Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.54 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | CPA2 | P48052 | 1/20 | 0.35 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CCKAR | P32238 | 1/20 | 0.34 |
| ▸ | CCKBR | P32239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15002721 | 0.98 | GLP1R (0.57) | GLP1RSELPNOD1C3AR1CCKAR | |
| SCHEMBL17131140 | 0.95 | GLP1R (0.57) | GLP1RSELPNOD1C3AR1CCKAR | |
| SCHEMBL16867531 | 0.94 | GLP1R (0.56) | GLP1RSELPNOD1C3AR1CPA1 | |
| SCHEMBL13694009 | 0.94 | GLP1R (0.53) | GLP1RSELPNOD1C3AR1CPA1 | |
| SCHEMBL14819787 | 0.92 | GLP1R (0.59) | GLP1RSELPNOD1CCKARCCKBR | |
| SCHEMBL15002720 | 0.92 | GLP1R (0.59) | GLP1RSELPNOD1CCKARCCKBR | |
| SCHEMBL18389177 | 0.91 | GLP1R (0.51) | GLP1RSELPNOD1C3AR1CPA1 | |
| SCHEMBL15002882 | 0.91 | GLP1R (0.51) | GLP1RSELPNOD1C3AR1CPA1 | |
| SCHEMBL12673948 | 0.91 | GLP1R (0.53) | GLP1RSELPNOD1C3AR1CPA1 | |
| SCHEMBL12673949 | 0.91 | GLP1R (0.56) | GLP1RSELPNOD1C3AR1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274801-A1 | ACYLATED GLUCAGON ANALOGUES | NOVO NORDISK AS (DK) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274801-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCG, IAPP | GLP1R 1/4885SELP 2972/4885NOD1 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.